For instance, by blocking both the Ras/Raf/MAPK and PI3K/AKT/mTOR pathways, PI-103, a potent inhibitor of AKT (Ser473) phosphorylation, combined with sorafenib was reported to synergistically inhibit epidermal growth factor (EGF)-stimulated HCC Huh7 cell proliferation (Gedaly et al., 2010). Here, EGF is linked to hepatocellular carcinoma.